Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2014 · 10-Q
Revenue$11.97M$11.97M+1.1% vs Q1 2013 Net Income-$26.55M-$26.55MN/M vs Q1 2013 EPS Diluted-$0.22-$0.22N/M vs Q1 2013 Gross Profit$3,048,000+296.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flow-$17,630,000N/M Free Cash Flowderived-$18,041,000N/M Margins · derivedGross margin25.5%+19.0 pt vs Q1 2013
Operating margin-210.8%−54.5 pt vs Q1 2013
Net margin-221.9%−58.9 pt vs Q1 2013
ended Mar 31, 2014 · filed May 12, 2014 · 42 d after period end